Latest News

The investigational anti–IL-13 monoclonal antibody could change how dermatologists think about biologic dosing in moderate to severe AD.

Imsidolimab gained EU orphan designation for GPP as the IL-36 receptor inhibitor advances toward a December 2026 FDA decision.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.

Are exosome-derived products legitimate or are they just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.

Split-face trial finds 34-gauge low-dead-space injector makes upper-face Botox injections hurt less, bruise less, and waste fewer units.

FDA clears RHA Redensity Eye for undereye hollows, offering soft, stretchable HA filler with 12-month results and strong safety data in a 52-week study.

Learn how private equity rollups reshape dermatology—EBITDA deals, MSOs, and the real tradeoffs for owners, PAs, and new grads.

Shanna Miranti, MPAS, PA-C, explores how fertility treatments can affect skin and hair, including acne, melasma, and hair loss, and offers guidance for patient care.

Meta-analysis suggests vitiligo links to lower skin cancer rates, with significantly reduced squamous cell carcinoma; phototherapy shows higher estimates but remains inconclusive.

Preclinical data show GX-03 reduced IL-31 by nearly 68% and dermatitis severity by 66% in a murine model of atopic dermatitis.

New research shows dermatologists continue to back daily sunscreen to prevent aging and skin cancer, debunking viral myths and spotlighting safer new filters coming to the US.

Joan Levy, PhD, chief science officer at the Melanoma Research Alliance, discussed the significance of Tudriqev's accelerated approval for patients with anti-PD-1-refractory melanoma.

Tattoo science goes skin deep, from ink placement and healing to adverse reactions, aftercare, and the dermatologic effects of pigment.